Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

In other news, the FDA moves to restrict use of fluoride supplements by children and the EPA approves more pesticides that some consider PFAS ...

Aurinia Pharmaceuticals Inc. (AUPH) has recently garnered a “Buy” rating from Jefferies analyst Maury Raycroft, a change that could have significant implications for investors. With a target price of ...

Fintel reports that on November 7, 2025, Jefferies upgraded their outlook for Aurinia Pharmaceuticals (NasdaqGM:AUPH) from ...

Reports suggest that, internally, the Food and Drug Administration is facing a crisis of confidence.

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Aurinia Pharmaceuticals Inc. (AUPH) received a recently updated rating from RBC Capital’s Douglas Miehm, who moved the stock to a “Sector Perform” designation o. This rating comes with a price target ...

Aurinia Pharmaceuticals (AUPH) stock slips as RBC Capital Markets downgrades the company following its better than expected ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

Fintel reports that on November 5, 2025, RBC Capital downgraded their outlook for Aurinia Pharmaceuticals (NasdaqGM:AUPH) ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Q3 2025 Earnings Call Transcript November 4, 2025 Aurinia Pharmaceuticals Inc.

Dr George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just days after he was placed on administrative leave while federal officials ...